Management Team and Consultants

Alex is Epirium’s Chief Executive Officer, and a member of the board of directors. He previously served as Chief Operating Officer, Chief Operating/Chief Financial Officer, and Chief Financial Officer. Alex has broad operational and financial expertise, with more than 25 years of experience as a successful healthcare executive and institutional investor. Before joining Epirium, Alex was the founder, Chief Executive Officer, and portfolio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as Chief Financial Officer of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals.

Alex was a founder and senior advisor at Casdin Advisors, LLC, Chief Executive Officer and Portfolio Manager at Cooper Hill Partners, LLC, a healthcare investment fund, and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the Dreyfus Corporation as a senior managing analyst covering pharmaceuticals, biotechnology, and medical devices.

Alex serves on the Board of Directors of Erasca, Inc., and is Chair of the Audit Committee. Alex has also served on the Boards of Directors for multiple life science companies, including Ignyta Inc. (acquired by Roche) and Dusa Pharmaceuticals, Inc. (acquired by Sun Pharma). He also served as an Investor Board Observer of 454 Life Sciences (acquired by Roche).

Alex is a member on Brown University’s Advisory Council on Biology and Medicine. He is also Treasurer, Executive Committee member, and Board member of The American Society of Clinical Oncology’s Conquer Cancer Foundation. Alex received an M.B.A. from Columbia Business School, Beta Gamma Sigma, and a B.A. in political science from Brown University.

Eric currently serves as our Chief Financial Officer and leads our accounting and finance functions. He joined Epirium as Vice President, Finance Operations and Chief Accounting Officer in January 2021, bringing over 20 years of finance experience, including over a decade in the life science industry at both commercial and clinical-stage companies. Prior to joining Epirium, Eric was the acting San Diego Site Head of Finance at Synthorx, Inc. after its acquisition by Sanofi. Previously, Eric held various roles with increasing responsibilities at Acadia Pharmaceuticals Inc., including Corporate Controller and Principal Accounting Officer. During his time at Acadia, Eric supported its first commercial launch and oversaw accounting, SEC reporting, treasury, and financial planning functions, as well as supported fundraising initiatives of over $1B in follow-on public offerings for the company. He also held roles with increasing responsibility at Cadence Pharmaceuticals (acquired by Mallinckrodt Pharmaceuticals).

Eric is a Certified Public Accountant with the State of California and holds a Bachelor of Science in Business Administration from Carnegie Mellon University.

Micah currently serves as our Senior Director, Translational Sciences and leads our Discovery Biology and Biomarker Development Programs. He joined Epirium as Director, Translational Sciences in September 2023, bringing over 7 years of experience in biotech drug discovery and development. Prior to joining Epirium, Micah was Associate Director, Translational Sciences at Scholar Rock where he supported Discovery Biology programs for myostatin inhibitors in neuromuscular and metabolic disease as well as new target validation in fibrosis. While at Scholar Rock, he led clinical biomarker strategy and contributed to preclinical development of apitegromab. Prior to starting a career in biotech, Micah received the Ruth L. Kirschstein National Research Service Award from the National Institutes of Health for his postdoctoral research fellowship on skeletal muscle stem cells and muscle regeneration in the lab of Chen-Ming Fan, Ph.D., at the Carnegie Institution for Science. 
 
Micah received a Ph.D. in cellular and molecular biology from Johns Hopkins University.